Clinical Trials / Studies
Cancer
Canine Appendicular Osteosarcoma
FULLY ENROLLED - Thank you for your participation!Dogs Receiving Doxorubicin
We are investigating the benefit of Fortiflora™ nutritional supplement in dogs receiving doxorubicin chemotherapy.
- Dogs already receiving doxorubicin are eligible.
- Fortiflora or placebo will be provided free-of-charge and clients will also receive a $212 credit toward treatment for participation.
- Dogs must return 3 and 7 days after doxorubicin treatment for blood and urine samples. These visits will be at no-cost for the client.
- Clients must fill out a diary regarding their dog's fecal scores for 10 days after doxorubicin treatment.
- Dogs on less-than-standard doses are not eligible.
Contact Dr. Andi Flory (760) 466-0600 or (858) 875-7500 x719.
Canine Solid Tumor and Mast Cell Tumor Trials
Trials examining novel biologic therapy for dogs with MEASUREABLE mast cell tumors and other solid tumors, excluding osteosarcoma.
Eligibility Criteria:
- Generally good health
- Potentially resectable, dermal or subcutaneous tumors measuring 1-7 cm in longest dimension (please call to discuss if tumors are larger than 7 cm as exceptions may be made)
Please call Dr. Brenda Phillips for information (858 )875-7500.
Internal Medicine
NEW* Effectiveness of Maropitant (Cerenia) in Cats with Liver Disease
Dr. Keith Richter is leading a study to determine how maropitant (Cerenia) is metabolized in cats with liver disease, and how effective it is as an antiemetic in cats with liver disease (compared with metoclopramide). We are actively recruiting cases, so if you have a cat with liver disease, please contact us. Clients receive significant financial incentives.
Please call Dr. Keith Richter at (858) 875-7500 for more information.
NEW* Feline Hepatic Lipidosis Study
We are now enrolling cats with confirmed hepatic lipidosis (HL) with the objective of evaluating vitamin-B metabolism and lipid profiles associated with this disease process. This is a 4-week prospective study which requires whole blood and urine collected at the time of diagnosis and at 2 and 4 week rechecks. The objective of this study is to expand our understanding of vitamin-B and lipid metabolism in cats with HL. Patients that have received cobalamin or folic acid supplementation within 8 weeks prior to diagnosis of HL may not be included in this study (supplementation is permitted following receipt of the first samples at the time of diagnosis).
For more information please contact Drs. Alexandra Hamilton or Steve Hill at (858) 875-7500.
Canine IBD and Probiotic VSL#3
We are enrolling dogs with chronic gastrointestinal signs that are suspected of having idiopathic inflammatory bowel disease (IBD). Endoscopy will be performed, and if IBD is confirmed, dogs will be randomized to receive treatment with prednisone and diet, or prednisone, diet and probiotic VSL#3. This is an 8-week study requiring two endoscopic procedures. The cost of the probiotic VSL#3 and the cost of the second endoscopy will be funded.
Contact Dr. Steve Hill at (858) 875-7500 x702.
Glomerular Disease Study
VSH is participating in a multi-center prospective study evaluating increased dosing of enalapril in dogs with glomerular disease. Client incentives include reduced cost of some initial testing and no cost for scheduled recheck visits and tests.
For more information please contact Dr. Julie Fischer at 760-466-0600.